# Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France

> **NCT07729852** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Alterity Therapeutics** · enrollment: 7 (estimated)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** ATH434

## Key facts

- **NCT ID:** NCT07729852
- **Lead sponsor:** Alterity Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-10-01
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729852, "Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07729852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*